Luo Yunbo, Ma Aimin, Huang Shengkai, Yu Yinghua
Department of Thyroid and Breast Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
Department of Breast Surgery, Wuming Hospital of Guangxi Medical University, Nanning, China.
Breast Care (Basel). 2022 Jun;17(3):296-305. doi: 10.1159/000521097. Epub 2021 Nov 26.
Invasive lobular carcinoma (ILC) is more likely to have bone metastasis than invasive ductal carcinoma (IDC). However, the prognosis for bone metastasis in ILC and IDC is barely known. So, the aim of this study was to investigate the difference of prognosis between ILC and IDC accompanied by bone metastasis.
We evaluated the women with bone-only metastasis of defined IDC or ILC reported to the Surveillance, Epidemiology and End Results program from 2010 to 2016. Pearson's χ test was used to compare the differences of clinicopathologic factors between IDC and ILC. Univariate and multivariate analyses were performed to verify the effects of histological types (IDC and ILC) and other clinicopathologic factors on the overall survival (OS) and cancer-specific survival (CSS).
Overall, 3,647 patients with IDC and 945 patients with ILC met the inclusion criteria and were analyzed in our study. The patients with ILC were more likely to be older and to have lower histological grade and a higher proportion of the HR*/HER2- subtype. However, less treatment was administered to ILC than IDC, such as surgery of the breast, radiation, and chemotherapy. Compared to patients with IDC, patients with ILC showed worse OS (median OS, 36 and 42 months, respectively, < 0.001) and CSS (median CSS, 39 and 45 months, respectively, < 0.001), especially in subgroups with HR*/HER2- subtype (OS, hazard ratio: 1.501, 95% CI 1.270-1.773, < 0.001; CSS, hazard ratio: 1.529, 95% CI 1.281-1.825, < 0.001), lower histological grade (I-II) (OS, hazard ratio: 1.411, 95% CI 1.184-1.683, < 0.001; CSS, hazard ratio: 1.488, 95% CI 1.235-1.791, < 0.001), or tumor burden, such as T (OS, hazard ratio: 1.693, 95% CI 1.368-2.096, < 0.001; CSS, hazard ratio: 1.76, 95% CI 1.405-2.205, < 0.001) and N (OS, hazard ratio: 1.451, 95% CI 1.171-1.799, = 0.001; CSS, hazard ratio: 1.488, 95% CI 1.187-1.865, = 0.001). Furthermore, older age, black race, unmarried status, higher tumor burden (T and N), triple-negative subtype, and higher histological grade were independent risk factors for both OS and CSS. Surgery of the breast and chemotherapy could significantly improve the prognosis for patients.
Patients with ILC have worse outcomes compared to those with IDC when associated with bone-only metastasis, especially in subgroups with lower histological grade or tumor burden. More effective treatment measures may be needed for ILC, such as cyclin-dependent kinase 4/6 inhibitors, new targeted drugs, etc.
与浸润性导管癌(IDC)相比,浸润性小叶癌(ILC)更易发生骨转移。然而,ILC和IDC骨转移的预后情况鲜为人知。因此,本研究旨在探讨ILC和IDC伴骨转移患者预后的差异。
我们评估了2010年至2016年向监测、流行病学和最终结果计划报告的仅发生骨转移的IDC或ILC女性患者。采用Pearson卡方检验比较IDC和ILC之间临床病理因素的差异。进行单因素和多因素分析以验证组织学类型(IDC和ILC)及其他临床病理因素对总生存期(OS)和癌症特异性生存期(CSS)的影响。
总体而言,3647例IDC患者和945例ILC患者符合纳入标准并纳入本研究分析。ILC患者更可能年龄较大,组织学分级较低,HR*/HER2-亚型比例较高。然而,与IDC患者相比,ILC患者接受的治疗较少,如乳房手术、放疗和化疗。与IDC患者相比,ILC患者的OS(中位OS分别为36个月和42个月,P<0.001)和CSS(中位CSS分别为39个月和45个月,P<0.001)更差,尤其是在HR*/HER2-亚型亚组(OS,风险比:1.501,95%CI 1.270-1.773,P<0.001;CSS,风险比:1.529,95%CI 1.281-1.825,P<0.001)、组织学分级较低(I-II级)(OS,风险比:1.411,95%CI 1.184-1.683,P<0.001;CSS,风险比:1.488,95%CI 1.235-1.791,P<0.001)或肿瘤负荷较高(如T(OS,风险比:1.693,95%CI 1.368-2.096,P<0.001;CSS,风险比:1.76,95%CI 1.405-2.205,P<0.001)和N(OS,风险比:1.451,95%CI 1.171-1.799,P=0.001;CSS,风险比:1.488,95%CI 1.187-1.865,P=0.001)亚组中。此外,年龄较大、黑人种族、未婚状态